Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986263

Next Previous
Drug Profile

BMS 986263

Alternative Names: BMS-986263; ND-L02-s0201

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nitto Denko
  • Developer Bristol-Myers Squibb; Nitto Denko
  • Class Antifibrotics; Hepatoprotectants; Small interfering RNA
  • Mechanism of Action HSP47 heat shock protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Liver cirrhosis
  • No development reported Fibrosis; Hepatic fibrosis

Most Recent Events

  • 09 Feb 2024 Bristol-Myers Squibb terminates a phase II trial in Liver cirrhosis in United Kingdom, Taiwan, Switzerland, Spain, Puerto Rico, South Korea, Japan, Italy, Israel, France, Canada, Brazil, Belgium, Argentina, USA (IV), due to lack of efficacy in the short term acute phase (NCT04267393)
  • 02 Jan 2023 BMS 986263 is still in phase II trials for Idiopathic-pulmonary-fibrosis in USA, Germany, Japan and UK (NCT03538301)
  • 02 Jan 2023 BMS 986263 is still in phase II trials for Liver cirrhosis in Germany (IV, Infusion) (NCT03420768)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top